about
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with ...
Read More
1.44
0.02
(1.41%)
4.8M
XNAS Volume
XNAS 17 Jul, 2026 5:30 PM (EDT)
Low Financial Strength
Expensive Valuation
Technically Neutral
Momentum Trap
These stocks have weak financials and expensive valuation. Medium technical scores may weaken. Investors should exercise caution
View Similar
Embed DVM
Geron Corp Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..